- Home
- ICLR vs VTRS Comparison
ICLR vs VTRS Comparison
Compare ICLR & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICLR
- VTRS
- Stock Information
- Founded
- ICLR 1990
- VTRS 1961
- Country
- ICLR Ireland
- VTRS United States
- Employees
- ICLR N/A
- VTRS N/A
- Industry
- ICLR Biotechnology: Commercial Physical & Biological Resarch
- VTRS Medicinal Chemicals and Botanical Products
- Sector
- ICLR Health Care
- VTRS Health Care
- Exchange
- ICLR Nasdaq
- VTRS Nasdaq
- Market Cap
- ICLR 11.6B
- VTRS 10.6B
- IPO Year
- ICLR 1998
- VTRS N/A
- Fundamental
- Price
- ICLR $150.41
- VTRS $9.15
- Analyst Decision
- ICLR Buy
- VTRS Hold
- Analyst Count
- ICLR 12
- VTRS 5
- Target Price
- ICLR $187.82
- VTRS $10.40
- AVG Volume (30 Days)
- ICLR 1.1M
- VTRS 10.6M
- Earning Date
- ICLR 07-23-2025
- VTRS 08-07-2025
- Dividend Yield
- ICLR N/A
- VTRS 5.26%
- EPS Growth
- ICLR 11.53
- VTRS N/A
- EPS
- ICLR 9.19
- VTRS N/A
- Revenue
- ICLR $8,192,621,999.00
- VTRS $14,330,200,000.00
- Revenue This Year
- ICLR N/A
- VTRS N/A
- Revenue Next Year
- ICLR $2.10
- VTRS $1.85
- P/E Ratio
- ICLR $16.55
- VTRS N/A
- Revenue Growth
- ICLR N/A
- VTRS N/A
- 52 Week Low
- ICLR $125.10
- VTRS $6.85
- 52 Week High
- ICLR $347.72
- VTRS $13.55
- Technical
- Relative Strength Index (RSI)
- ICLR 57.67
- VTRS 54.81
- Support Level
- ICLR $146.56
- VTRS $9.17
- Resistance Level
- ICLR $155.90
- VTRS $9.39
- Average True Range (ATR)
- ICLR 4.88
- VTRS 0.21
- MACD
- ICLR 0.23
- VTRS 0.00
- Stochastic Oscillator
- ICLR 57.80
- VTRS 63.82
About ICLR ICON plc
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.
About VTRS Viatris Inc.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.